Vimta Labs to invest Rs. 50 crores to Biologics CDMO business foray

The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides

Sumitomo Chemical establishes a CRO for Oligonucleotide CDMO business in US

Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013

Amaran Biotech signs MOU with Nippon Fine Chemical to expand CDMO business

Amaran Biotech boasts Taiwan’s first fully automated robotic aseptic filling line, offering high-quality and low-waste filling solutions for high-value pharmaceuticals

Granules India acquires Swiss Senn Chemicals to foray into peptide and CDMO business

The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market

Hikal appoints Dr. Raghavendar Morthala as Head – CDMO R&T Pharma & Animal Health BU

Nutraceuticals CDMO manufacturer Crius Group to adopt 100% AI-based project implementation

NutrifyGenie AI, a leading AI-driven platform, was integral in designing scientifically differentiated formulations for a multinational client

Akums signs Rs. 1,760 crore CDMO agreement with a leading global pharma company

The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities

Shilpa Medicare’s acceptance by USFDA of NDA filed by its CDMO partner Unicycive for Oxylanthanum Carbonate

Strides Pharma's CDMO arm OneSource raises Rs. 801 crore in pre-listing round

The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion

Shilpa Medicare’s CDMO customer gets fast-track designation for its investigational drug candidate

GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally